Millennium Pharmaceuticals, Inc.

Clinical trials sponsored by Millennium Pharmaceuticals, Inc., explained in plain language.

Now part of Takeda Pharmaceutical Company Limited TAK NYSE

Biopharma focused on oncology, now part of Takeda.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Terminated 1

Promising drug combo for rare amyloidosis hits snag: trial ends early

Disease control Stopped early

This study tested a drug called ixazomib plus dexamethasone against other standard treatments for people with relapsed AL amyloidosis, a rare disease where abnormal proteins build up in organs. The trial aimed to see if the combination improved blood markers and slowed heart or k…

Phase 3 • Sponsor: Millennium Pharmaceuticals, Inc. • Aim: Disease control

Last updated Jun 26, 2026 13:13 UTC

Millennium Pharmaceuticals, Inc.

Promising drug combo for rare amyloidosis hits snag: trial ends early